Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 May;27(3):e368-e375.
doi: 10.1111/hae.14301. Epub 2021 Mar 29.

Haemophilia A patients' medication adherence to prophylaxis with efmoroctocog alfa

Victoire Pitance  1 , Stéphanie Désage  1 , Anne Lienhart  1 , Sandrine Meunier  1 , Valérie Chamouard  1   2
Affiliations
Observational Study

Haemophilia A patients' medication adherence to prophylaxis with efmoroctocog alfa

Victoire Pitance et al. Haemophilia. 2021 May.

Abstract

Introduction: Lightening the injection burden is commonly believed to improve prophylaxis adherence. Efmoroctocog alfa (rFVIIIFc) is the first recombinant FVIII-Fc fusion protein available in France. This clotting factor with an extended half-life could thus improve medication adherence.

Aim: The study primarily aimed to assess the real-life impact on prophylaxis adherence of haemophilia A patients, when switching from a standard to an extended half-life FVIII.

Methods: This study was an observational, monocentre, non-interventional study aiming at assessing haemophilia A patients' real-life adherence during the first-year post-rFVIIIFc prophylaxis initiation. Medication adherence was assessed using two methods: the medication possession ratio (MPR), which is based on the hospital pharmacy dispensing data, and self-reported VERITAS-Pro® questionnaire. Patients on rFVIIIFc prophylaxis for at least 12 months, following a 12-month standard FVIII prophylaxis, were eligible for inclusion.

Results: In 2019, 47 male patients were undergoing rFVIIIFc prophylaxis in our Hemophilia Center, among which 36 meeting the inclusion criteria. Switching from standard to extended half-life FVIII prophylaxis resulted in increased mean dosing, while the mean number of weekly prophylactic injections (2.6 ± 0.5 vs 1.8 ± 0.3) decreased. Following rFVIIIFc initiation, a non-significant increase in median MPR occurred and the self-reported VERITAS-Pro® questionnaire demonstrated improved adherence to rFVIIIFc prophylaxis. Comparing adherent and non-adherent patients revealed age as the only factor likely to impact adherence (p = .07).

Conclusion: Our patient cohort exhibited high adherence levels before and after FVIII switching, based on MPR and VERITAS-Pro® questionnaire. The latter is likely a useful tool to quantity prophylaxis adherence from a patient's perspective in daily use.

Keywords: efmoroctocog alfa; extended half-life coagulation factor; haemophilia; medication adherence; prophylaxis; rFVIIIFc.

PubMed Disclaimer

References

REFERENCES

    1. National Hemophilia Foundation. Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). New York National Hemophilia Foundation; 2007. Report no. MASAC 179.
    1. Björkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet. 2001;40:815-832.
    1. Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol. 2009;65:989-998.
    1. Biogen Inc Eloctate® [Antihemophilic Factor (Recombinant), Fc Fusion Protein]: US Prescribing Information. 2016. http://www.eloctate.com. Accessed February 29, 2020.
    1. Nolan B, Mahlangu J, Perry D, et al. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with Haemophilia A. Haemophilia. 2015;22:72-80.

Publication types

LinkOut - more resources